Deposition of Alzheimer's vascular amyloid-β is associated with decreased expression of brain L-3-hydroxyacyl-coenzyme A dehydrogenase (ERAB)

Janusz Frackowiak, Bozena Mazur-Kolecka, Wojciech Kaczmarski, Dennis W Dickson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

L-3-hydroxyacyl-coenzyme A dehydrogenase type II (HADH) was described as an endoplasmic reticulum amyloid β-peptide-binding protein (ERAB), which enhances Aβ toxicity, and accumulates in neurons in Alzheimer's disease (AD). Hence, HADH/ERAB was suggested to mediate the amyloid-induced neurodegeneration. We estimated the in vivo interactions of HADH and Aβ in an immunocytochemical study of ten Alzheimer's disease and seven normal brains using five monoclonal HADH-specific antibodies. We found no HADH in amyloid plaques or vascular amyloid. The neuronal expression of HADH was not correlated with the severity of amyloid load in neuropil. HADH was expressed in vascular smooth muscle cells in young and old controls and in amyloid-free blood vessels in AD cases, but little or no HADH was in smooth muscle cells in arteries with amyloid deposits. The putative intracellular interaction between HADH and Aβ in amyloid-producing cells was further studied in vascular smooth muscle cells isolated from brain blood vessels with amyloid-β angiopathy - the cells that were shown previously to accumulate Aβ intracellularly ['Research advances in Alzheimer's disease and related disorders' (1995) 747; Brain Res. 676 (1995) 225; Neurosci. Lett. 183 (1995) 120]. HADH had a mitochondrial localization and did not co-localize with an endoplasmic reticulum marker. Cells that accumulated Aβ were those with low expression of HADH and the proteins did not co-localize. Explanation of the association between low levels of HADH and deposition of Aβ by brain smooth muscle cells requires further studies.

Original languageEnglish (US)
Pages (from-to)44-53
Number of pages10
JournalBrain Research
Volume907
Issue number1-2
DOIs
StatePublished - Jul 13 2001

Fingerprint

Coenzyme A
Amyloid
Endoplasmic Reticulum
Blood Vessels
Carrier Proteins
Oxidoreductases
Peptides
Brain
Smooth Muscle Myocytes
Alzheimer Disease
Amyloid Plaques
Vascular Smooth Muscle
Neuropil
Arteries
Neurons
Antibodies
Research
Proteins

Keywords

  • Aβ-blinding protien
  • Alzheimer's disease
  • Cell culture
  • ERAB
  • L-3-hydroxyacyl-coenzyme A dehydrogenase
  • Smooth muscle cells
  • Vascular amyloidosis

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Deposition of Alzheimer's vascular amyloid-β is associated with decreased expression of brain L-3-hydroxyacyl-coenzyme A dehydrogenase (ERAB). / Frackowiak, Janusz; Mazur-Kolecka, Bozena; Kaczmarski, Wojciech; Dickson, Dennis W.

In: Brain Research, Vol. 907, No. 1-2, 13.07.2001, p. 44-53.

Research output: Contribution to journalArticle

@article{0af82695559a4fb4bf2dc02bed94d5eb,
title = "Deposition of Alzheimer's vascular amyloid-β is associated with decreased expression of brain L-3-hydroxyacyl-coenzyme A dehydrogenase (ERAB)",
abstract = "L-3-hydroxyacyl-coenzyme A dehydrogenase type II (HADH) was described as an endoplasmic reticulum amyloid β-peptide-binding protein (ERAB), which enhances Aβ toxicity, and accumulates in neurons in Alzheimer's disease (AD). Hence, HADH/ERAB was suggested to mediate the amyloid-induced neurodegeneration. We estimated the in vivo interactions of HADH and Aβ in an immunocytochemical study of ten Alzheimer's disease and seven normal brains using five monoclonal HADH-specific antibodies. We found no HADH in amyloid plaques or vascular amyloid. The neuronal expression of HADH was not correlated with the severity of amyloid load in neuropil. HADH was expressed in vascular smooth muscle cells in young and old controls and in amyloid-free blood vessels in AD cases, but little or no HADH was in smooth muscle cells in arteries with amyloid deposits. The putative intracellular interaction between HADH and Aβ in amyloid-producing cells was further studied in vascular smooth muscle cells isolated from brain blood vessels with amyloid-β angiopathy - the cells that were shown previously to accumulate Aβ intracellularly ['Research advances in Alzheimer's disease and related disorders' (1995) 747; Brain Res. 676 (1995) 225; Neurosci. Lett. 183 (1995) 120]. HADH had a mitochondrial localization and did not co-localize with an endoplasmic reticulum marker. Cells that accumulated Aβ were those with low expression of HADH and the proteins did not co-localize. Explanation of the association between low levels of HADH and deposition of Aβ by brain smooth muscle cells requires further studies.",
keywords = "Aβ-blinding protien, Alzheimer's disease, Cell culture, ERAB, L-3-hydroxyacyl-coenzyme A dehydrogenase, Smooth muscle cells, Vascular amyloidosis",
author = "Janusz Frackowiak and Bozena Mazur-Kolecka and Wojciech Kaczmarski and Dickson, {Dennis W}",
year = "2001",
month = "7",
day = "13",
doi = "10.1016/S0006-8993(01)02497-0",
language = "English (US)",
volume = "907",
pages = "44--53",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Deposition of Alzheimer's vascular amyloid-β is associated with decreased expression of brain L-3-hydroxyacyl-coenzyme A dehydrogenase (ERAB)

AU - Frackowiak, Janusz

AU - Mazur-Kolecka, Bozena

AU - Kaczmarski, Wojciech

AU - Dickson, Dennis W

PY - 2001/7/13

Y1 - 2001/7/13

N2 - L-3-hydroxyacyl-coenzyme A dehydrogenase type II (HADH) was described as an endoplasmic reticulum amyloid β-peptide-binding protein (ERAB), which enhances Aβ toxicity, and accumulates in neurons in Alzheimer's disease (AD). Hence, HADH/ERAB was suggested to mediate the amyloid-induced neurodegeneration. We estimated the in vivo interactions of HADH and Aβ in an immunocytochemical study of ten Alzheimer's disease and seven normal brains using five monoclonal HADH-specific antibodies. We found no HADH in amyloid plaques or vascular amyloid. The neuronal expression of HADH was not correlated with the severity of amyloid load in neuropil. HADH was expressed in vascular smooth muscle cells in young and old controls and in amyloid-free blood vessels in AD cases, but little or no HADH was in smooth muscle cells in arteries with amyloid deposits. The putative intracellular interaction between HADH and Aβ in amyloid-producing cells was further studied in vascular smooth muscle cells isolated from brain blood vessels with amyloid-β angiopathy - the cells that were shown previously to accumulate Aβ intracellularly ['Research advances in Alzheimer's disease and related disorders' (1995) 747; Brain Res. 676 (1995) 225; Neurosci. Lett. 183 (1995) 120]. HADH had a mitochondrial localization and did not co-localize with an endoplasmic reticulum marker. Cells that accumulated Aβ were those with low expression of HADH and the proteins did not co-localize. Explanation of the association between low levels of HADH and deposition of Aβ by brain smooth muscle cells requires further studies.

AB - L-3-hydroxyacyl-coenzyme A dehydrogenase type II (HADH) was described as an endoplasmic reticulum amyloid β-peptide-binding protein (ERAB), which enhances Aβ toxicity, and accumulates in neurons in Alzheimer's disease (AD). Hence, HADH/ERAB was suggested to mediate the amyloid-induced neurodegeneration. We estimated the in vivo interactions of HADH and Aβ in an immunocytochemical study of ten Alzheimer's disease and seven normal brains using five monoclonal HADH-specific antibodies. We found no HADH in amyloid plaques or vascular amyloid. The neuronal expression of HADH was not correlated with the severity of amyloid load in neuropil. HADH was expressed in vascular smooth muscle cells in young and old controls and in amyloid-free blood vessels in AD cases, but little or no HADH was in smooth muscle cells in arteries with amyloid deposits. The putative intracellular interaction between HADH and Aβ in amyloid-producing cells was further studied in vascular smooth muscle cells isolated from brain blood vessels with amyloid-β angiopathy - the cells that were shown previously to accumulate Aβ intracellularly ['Research advances in Alzheimer's disease and related disorders' (1995) 747; Brain Res. 676 (1995) 225; Neurosci. Lett. 183 (1995) 120]. HADH had a mitochondrial localization and did not co-localize with an endoplasmic reticulum marker. Cells that accumulated Aβ were those with low expression of HADH and the proteins did not co-localize. Explanation of the association between low levels of HADH and deposition of Aβ by brain smooth muscle cells requires further studies.

KW - Aβ-blinding protien

KW - Alzheimer's disease

KW - Cell culture

KW - ERAB

KW - L-3-hydroxyacyl-coenzyme A dehydrogenase

KW - Smooth muscle cells

KW - Vascular amyloidosis

UR - http://www.scopus.com/inward/record.url?scp=0035854582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035854582&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(01)02497-0

DO - 10.1016/S0006-8993(01)02497-0

M3 - Article

C2 - 11430884

AN - SCOPUS:0035854582

VL - 907

SP - 44

EP - 53

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -